SwedenSweden

Viragen Will Produce in Sweden

06.08.2004

Plantation - US-based Viragen Inc. confirmed in mid-July that its Swedish manufacturing facility in Ersboda is on schedule to commence with the production of Multiferon™ in September. The company has been upgrading and expanding its production capabilities as a result of a more aggressive business direction for its natural human alpha interferon drug. Viragen previously reported that it expects to report data later this year from studies evaluating Multiferon for the treatment of malignant melanoma. “The combined manufacturing capabilities of our existing facility in Umeå with our new facility in Ersboda will provide us with the compliance and capacity necessary to focus on our goal to make Multiferon the world's most prescribed natural human alpha interferon,” stated Viragen's CEO Charles Rice. The construction of the Ersboda facility was completed earlier this year and is currently undergoing validation required by the Swedish regulatory authorities.

SwedenSweden

12.03.2012

Gothenburg – Researchers at the Sahlgrenska Academy have discovered a previously unknown mechanism which helps intestinal bacteria to affect the formation of blood vessels. In a study of mice, the team led by Fredrik Bäckhed...

SwedenSweden

08.03.2012

Swiss Nestlé S.A. has extended its collaboration agreement with BioGaia AB. The world’s largest nutrition company is paying up to €50.8m for a perpetual licence to use BioGaia’s patented Lacto­bacillus reuteri in infant nutrition...

SwedenSweden

08.03.2012

Stockholm – Swedish drug delivery specialist Orexo AB has announced the intention to cut its headcount by 30% in order to reduce the company's burn rate. The personnel reduction by 35 people is expected to lower the costs by a...

SwedenSweden

07.03.2012

After a long period of negotiations, Sweden’s Orexo AB and Belgium’s Janssen Pharmaceutica have terminated their joint research programmes. “Unfortunately, we lack the funds to continue on our own to develop the OX-CLI and OX-ESI...

SwedenSweden

06.03.2012

Uppsala/Moscow – Vaccine adjuvant specialist Isconova AB is set to begin receiving royalties and product revenues from Russian partner VetBioChem. The veterinary medicine company has launched two new rabies vaccines for dogs and...

SwedenSweden

23.02.2012

Stockholm - Probiotics can help prevent diseases, Swedish researchers have found out. The results are in sharp contrast with all health claim judgements involving probiotics published by the EU's food watchdog EFSA up to now. The...

SwedenSweden

16.02.2012

Huddinge – Full stop for one of Sweden's most promising biotech companies. Karo Bio has terminated the trial of its late-stage cholesterol drug eprotirome and won't proceed with its plans to spin off its preclinical operations....

SwedenSweden

19.12.2011

Helsingborg/Exton – Swedish drug developer DuoCort Pharma AB has been purchased by US-based biopharmaceuticals maker ViroPharma Inc. ViroPharma paid around €25m up front, but DuoCort’s former owners could end up receiving €97m...

SwedenSweden

15.12.2011

Stockholm/Cologne – Researchers at the Swedish Karolinska Institute and the University of Cologne have identified a new protein-based defense mechanism against cancer (Struct. & Molec. Biology, doi: 10.1038/10.1038/nsmb.2188)....

SwedenSweden

15.12.2011

Craigavon/Uppsala – Irish Almac Discovery, a member of the Almac Group, will begin cooperating with Uppsala-based Beactica AB to develop new cancer drug candidates. In late November, the companies announced that Beactica’s Sprint...

Displaying results 1 to 10 out of 182

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-sweden/article/viragen-will-produce-in-sweden.html

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • CO.DON2.65 EUR6.00%
  • FORMYCON10.90 EUR4.51%
  • CYTOS0.29 CHF3.57%

FLOP

  • BIOTEST79.48 EUR-2.68%
  • ADDEX2.99 CHF-1.97%
  • EVOTEC3.23 EUR-1.22%

TOP

  • CYTOS0.29 CHF81.2%
  • EPIGENOMICS5.16 EUR46.2%
  • FORMYCON10.90 EUR38.9%

FLOP

  • THERAMETRICS0.07 CHF-12.5%
  • BIOFRONTERA2.59 EUR-10.7%
  • ADDEX2.99 CHF-9.4%

TOP

  • SANTHERA92.95 CHF2525.7%
  • CO.DON2.65 EUR154.8%
  • BB BIOTECH183.40 EUR63.9%

FLOP

  • CYTOS0.29 CHF-91.3%
  • 4SC0.90 EUR-48.0%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 25.11.2014

Current issue

All issues